Q-omics provides the consensus-scored MT4 profile across patient tissues and cancer cell-line models. MT4 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MT4 is differentially expressed in 2, with the highest sampling consensus in UCEC. Additionally, MT4 RNA expression shows 9,329 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, UCEC, and TGCT as cancer lineages where MT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT4 survival associations across molecular data types. MT4 RNA expression shows survival associations in the most cancer types (11), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT4 RNA expression–survival associations across cancer types. High MT4 expression shows unfavorable associations in ACC, LUAD, LUSC, HNSC and SKCM, but favorable associations in STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MT4 RNA expression.
This table summarizes MT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT4 shows lower tumor expression in THCA and higher tumor expression in UCEC. The UCEC box plot shows higher MT4 RNA expression in tumor versus normal tissue (log2 FC = +1.443, t-test p = .032).
This table shows molecular features associated with MT4 in patient tissues and cancer cell lines. In patient samples, MT4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
